Group 1 - The company approved a profit distribution plan for the year 2024, proposing a cash dividend of RMB 0.45 per 10 shares, totaling RMB 12,287,141.82 (including tax) based on a total share capital of 273,047,596 shares as of the announcement date [1][2] - Following a share cancellation, the total share capital will be adjusted to 273,046,796 shares, but the cash dividend per share will remain unchanged [1][2] - The actual distribution will be based on the total share capital as of the record date, which is set for July 10, 2025, with the ex-dividend date on July 11, 2025 [3] Group 2 - The company will not withhold individual income tax for shareholders, and tax will be calculated based on the holding period when shares are sold [2][3] - Different tax rates will apply for overseas institutions and individual investors holding pre-IPO restricted shares, with a 10% tax rate for Hong Kong investors on fund shares [2][3] - The distribution plan is subject to adjustments if the total share capital changes before the implementation [2]

北京诚益通控制技术集团股份有限公司 2024 年年度权益分派实施公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 证券代码：300430 证券简称：诚益通 公告编号：2025-032 1、北京诚益通控制技术集团股份有限公司（以下简称"公司"）2024 年年 度股东大会审议通过的 2024 年度利润分配方案为：拟以截至披露利润分配方案 公告日的公司总股本 273,047,596 股为基数，向全体股东每 10 股派发现金股利 人民币 0.45 元（含税），合计派发现金股利人民币 12,287,141.82 元（含税）； 2、自 2024 年度利润分配方案披露至实施期间，公司总股本因股权激励回购 注销事项由 273,047,596 股变更为 273,046,796 股，将按照每股分配金额不变， 相应调整分配总额。本次权益分派实施后计算除权除息价格时，按公司最新总股 本折算的每 10 股现金分红=现金分红总额÷总股本（含回购股份）×10 股 =12,287,105.82 元/273,046,796×10 股=0.450000 元（保留六位小数）。本次 ...

| 投资主体 | 受托方 | 关联 | 产品名称 | 产品 | 委托理财金 | 起息日 | 到期日 | 预期年化收 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | 关系 | | 类型 | 额（万元） | | | 益率 | | 北京诚益通控 | | | 天添利现金 | | | 2025 年 6 | 2025 年 6 | | | 制技术集团股 | 浦发银行 | 否 | | 现金管理类 | 1750 | | | 1.7%～3% | | | | | 宝 | | | 月 11 日 | 月 26 日 | | | 份有限公司 | | | | | | | | | | 北京诚益通控 | | | | | | 2025 年 6 | 2025 年 6 | 1.80%～ | | 制技术集团股 | 江苏银行 | 否 | 苏银理财恒 | 固定收益类 | 1000 | | | | | 份有限公司 | | | 源灵动 | | | 月 13 日 | 月 23 日 | 2.60% | | 北京诚益通控 制技术集团股 | | | 民生理财天 | | | 2025 年 6 ...

A股市场热点不断，近期，"脑机接口"概念火了。 21世纪经济报道记者注意到，在上周大涨之后，6月23日，脑机接口板块继续上扬，塞力医疗 （603716）（603716.SH）"10CM"涨停，三博脑科（301293）（301293.SZ）涨幅超5%，佳禾智能 （300793）（300793.SZ）、麒盛科技（603610）（603610.SH）涨幅3%以上、诚益通（300430） （300430.SZ）、狄耐克（300884）（300884.SZ）、乐普医疗（300003）（300003.SZ）、熵基科技 （301330）（301330.SZ）涨幅2%以上。 与此同时，投资者涌向上市公司互动平台，密集询问公司脑机接口相关布局。从机构调研的角度看，近 两个月已有不少机构提前嗅到了相关机遇，了解脑机接口相关业务。 就脑机接口的产业链机遇而言，浙商证券（601878）指出，产业应用上，该市场仍以医疗为主。未来在 教育、游戏、智能家居等领域的应用占比将逐步提升。软件层面，人工智能技术的高速发展将为脑机接 口带来更多的创新机会；硬件层面，更高精度的传感器正在被开发，设备越来越轻便、便携，侵入性与 人体的兼容性正在持续改 ...

Group 1 - The brain-computer interface sector experienced a decline of 3.34%, ranking among the top losers in the concept sector as of the market close on June 20 [1][2] - Within the brain-computer interface sector, major companies such as Hanwei Technology, Nanjing Panda, and Aipeng Medical saw significant declines, while only two stocks, Haige Communication and ST Huatuo, recorded gains of 1.46% and 1.05% respectively [1][2] - The sector faced a net outflow of 546 million yuan from main funds, with 23 stocks experiencing net outflows, and seven stocks seeing outflows exceeding 30 million yuan [2] Group 2 - Hanwei Technology led the outflow with a net withdrawal of 133 million yuan, followed by Innovative Medical and Tom Cat with outflows of 129 million yuan and 116 million yuan respectively [2][3] - The stocks with the highest net inflows included ST Huatuo, Haige Communication, and Lepu Medical, with inflows of 58.93 million yuan, 35.06 million yuan, and 23.44 million yuan respectively [2][3] - The trading volume for Hanwei Technology was 12.95%, indicating a high turnover rate despite the decline of 6.59% in its stock price [2][3]

Group 1 - The brain-computer interface (BCI) concept has seen a significant surge, with related stocks experiencing substantial gains, including Beiyikang reaching a "30CM" limit up and Aipeng Medical hitting a "20CM" limit up [1][2] - The first humanoid robot full industry chain exhibition in China is set to take place on June 20 in Hangzhou, featuring Tesla and Yushu, showcasing advanced technologies including bionic drive and BCI [1][4] - The BCI market in China is projected to reach 5.58 billion yuan by 2027, indicating rapid growth and commercialization potential [1][6] Group 2 - Chinese concept stocks related to BCI have seen a significant rise, with companies like Aipeng Medical and Nanjing Panda Electronics experiencing limit up and substantial gains [2][3] - Nanjing Panda Electronics is developing a multimodal human-computer interaction system based on BCI technology, targeting applications in medical rehabilitation and smart wearables [3] - The market for BCI applications is expected to reach hundreds of billions of dollars, driven by various favorable developments and advancements in technology [4][6] Group 3 - The global BCI market is estimated to reach between 4 billion to 145 billion dollars in the medical field by 2030-2040, with non-invasive products currently leading commercialization [5][6] - The global BCI market size reached 1.98 billion dollars in 2023, with expectations to exceed 6 billion dollars by 2028, reflecting a compound annual growth rate of 25.22% [6]

Group 1 - The A-share market saw a significant rise in neuro-interface concept stocks, with companies like Aipeng Medical and Innovation Medical hitting the daily limit up [1] - Other companies such as Nanjing Panda, Sanbo Brain Science, Chengyitong, and Xiangyu Medical also opened high [1]

Group 1 - The brain-computer interface concept is gaining initial traction, with companies such as Innovent Medical (002173) and Aipeng Medical (300753) hitting the daily limit up [1] - Other companies like Nanjing Panda (600775), Sanbo Neuroscience (301293), Chengyitong (300430), and Dineike (300884) also opened significantly higher [1] - Overnight, US stocks in the brain regeneration technology sector surged by 283% [1]

Group 1: Industry Development - The first invasive brain-computer interface (BCI) clinical trial in China has been successfully conducted, marking a significant breakthrough in the technology, making China the second country globally to enter this phase after the United States [1] - The BCI technology is rapidly advancing, transitioning from laboratory research to clinical applications, with various policies being implemented to support its development [2][3] - The market size for China's BCI industry is projected to reach 3.2 billion yuan in 2024, with an annual growth rate of 18.8%, expected to increase to 5.5 billion yuan by 2027 [3] Group 2: Company Initiatives - Several listed companies are increasing their R&D investments in BCI technology, exploring applications in healthcare and entertainment [4] - Beijing Chengyitong Technology Group has established a dual-track strategy focusing on both invasive and non-invasive BCI technologies, aiming to enhance existing rehabilitation devices and conduct foundational research [4] - Henan Xiangyu Medical Equipment Co., Ltd. has developed a series of wireless EEG acquisition systems for various rehabilitation scenarios, indicating a proactive approach to integrating BCI technology into medical applications [4]

北京诚益通控制技术集团股份有限公司 关于部分限制性股票回购注销完成的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重要内容提示： 1、北京诚益通控制技术集团股份有限公司（以下简称"公司"）本次回购 注销限制性股票 800 股，占回购注销前公司总股本 273,047,596 股的 0.0003%， 回购价格 5.54 元/股，涉及激励对象 1 人。 证券代码：300430 证券简称：诚益通 公告编号：2025-029 2、截至本公告披露日，本次回购注销事项已在中国证券登记结算有限责任 公司深圳分公司办理完成。 3、本次回购注销完成后，公司总股本由 273,047,596 股变更为 273,046,796 股。 一、股权激励计划及本次回购注销已履行的审批程序 1、2021 年 10 月 27 日，公司召开第四届董事会第九次会议、第四届监事会 第九次会议，审议通过了《关于<北京诚益通控制工程科技股份有限公司 2021 年限制性股票激励计划（草案）>及其摘要的议案》等议案，公司独立董事对本 次激励计划的相关议案发表了独立意见，律师出具了法律意见书。 2、202 ...